208 related articles for article (PubMed ID: 12879633)
1. [Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].
Zeitlinger M; Müller M
Wien Med Wochenschr; 2003; 153(11-12):250-4. PubMed ID: 12879633
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
3. Controversy surrounding the safety of cerivastatin.
Davidson MH
Expert Opin Drug Saf; 2002 Sep; 1(3):207-12. PubMed ID: 12904136
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyolysis and statin therapy: relevance to the elderly.
Sica DA; Gehr TW
Am J Geriatr Cardiol; 2002; 11(1):48-55. PubMed ID: 11773716
[TBL] [Abstract][Full Text] [Related]
5. [Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].
Sparing R; Sellhaus B; Noth J; Block F
Nervenarzt; 2003 Feb; 74(2):167-71. PubMed ID: 12596018
[TBL] [Abstract][Full Text] [Related]
6. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
Psaty BM; Furberg CD; Ray WA; Weiss NS
JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
[TBL] [Abstract][Full Text] [Related]
7. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
Evans M; Rees A
Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
[TBL] [Abstract][Full Text] [Related]
8. Safety considerations for statins.
Bolego C; Baetta R; Bellosta S; Corsini A; Paoletti R
Curr Opin Lipidol; 2002 Dec; 13(6):637-44. PubMed ID: 12441888
[TBL] [Abstract][Full Text] [Related]
9. Preventive effects of bicarbonate on cerivastatin-induced apoptosis.
Kobayashi M; Kaido F; Kagawa T; Itagaki S; Hirano T; Iseki K
Int J Pharm; 2007 Aug; 341(1-2):181-8. PubMed ID: 17553641
[TBL] [Abstract][Full Text] [Related]
10. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Jamal SM; Eisenberg MJ; Christopoulos S
Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
[TBL] [Abstract][Full Text] [Related]
11. Cerivastatin and gemfibrozil-associated rhabdomyolysis.
Bruno-Joyce J; Dugas JM; MacCausland OE
Ann Pharmacother; 2001 Sep; 35(9):1016-9. PubMed ID: 11573847
[TBL] [Abstract][Full Text] [Related]
12. Cerivastatin-induced rhabdomyolysis: 11 case reports.
Ravnan SL; Locke C; Yee WP; Haase K
Pharmacotherapy; 2002 Apr; 22(4):533-7. PubMed ID: 11939690
[TBL] [Abstract][Full Text] [Related]
13. [Fatal rhabdomyolysis caused by cerivastatin].
Scheen AJ
Rev Med Liege; 2001 Aug; 56(8):592-4. PubMed ID: 11584446
[TBL] [Abstract][Full Text] [Related]
14. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.
von Keutz E; Schlüter G
Am J Cardiol; 1998 Aug; 82(4B):11J-17J. PubMed ID: 9737641
[TBL] [Abstract][Full Text] [Related]
15. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
16. Statins and myotoxicity: a therapeutic limitation.
Tiwari A; Bansal V; Chugh A; Mookhtiar K
Expert Opin Drug Saf; 2006 Sep; 5(5):651-66. PubMed ID: 16907655
[TBL] [Abstract][Full Text] [Related]
17. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
18. [Safety profile of statins].
Prieto JC
Rev Med Chil; 2001 Nov; 129(11):1237-40. PubMed ID: 11836874
[TBL] [Abstract][Full Text] [Related]
19. Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Backman JT; Kyrklund C; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2002 Dec; 72(6):685-91. PubMed ID: 12496749
[TBL] [Abstract][Full Text] [Related]
20. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions.
Mück W
Drugs; 1998; 56 Suppl 1():15-23; discussion 33. PubMed ID: 9740537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
